Inactivation by slow acting inhibitors in plasma is of little consequence for thrombolysis with wild type t-PA, since it is rapidly cleared from the blood stream and constantly replenished through infusion. However, it becomes increasingly important as the clearance rate of t-PA is reduced, through mutagenesis, to enable the molecule to be long acting and administered by a single bolus injection. The substitution of serine for alanine at position 473 substantially reduced the slow inactivation that occurs at pharmacological levels of t-PA in plasma. Approximately 70% of the activity of A473S remained after 4 h incubation in human plasma compared to approximately 25% for wild type t-PA. Wild type t-PA and A473S showed the same stability in alpha-2-antiplasmin depleted plasma, indicating that the resistance of A473S to inactivation is a result of reduced reactivity towards alpha-2-antiplasmin, the primary slow acting inhibitor of t-PA. The second order rate constant for the inactivation of A473S by purified alpha-2-antiplasmin was approximately 4 fold less than that of wild type t-PA, which is consistent with the results obtained in plasma. Substitution of threonine at position 473 also produced inhibitor resistance, but glycine did not. The substitution of charged or bulky residues at position 473 destroyed enzymatic activity. The mechanism of inhibitor resistance for A473S and A473T appears to be a reduced reactivity towards substrates with arginine at the PI position. The A473S mutation adds well to T103N, a mutation that causes an approximate 9 fold reduction in the clearance rate of t-PA. The double mutation variant, T103N, A473S had normal plasma clot lysis activity, and was stable in plasma over a 4 h incubation period at 37° C in vitro.
References
1
Pennica D,
Holmes WE,
Kohr WJ,
Harkins RN,
Vehar GA,
Ward CA,
Bennett WF,
Yelverton E,
Seeburg PH,
Heyneker HL,
Goeddel DV,
Collen D.
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-221
3
Topol EJ,
Califf RM,
George BS,
Kereiakes DJ,
Lee KL.
for the TAMI Study Group Insight derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) Trials. J Am Coll Cardiol 1988; 12: 24A-31A
4
Stump DC,
Calif RM,
Topol EJ,
Sigmon K,
Thornton D,
Masek R,
Anderson L,
Collen D.
and the TAMI Study Group Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222-1230
5 The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-627
7
Parker JA,
Markis JE,
Palla A,
Goldhaber SZ,
Royal HD,
Tumeh S,
Kim D,
Rustgi AK,
Holman BL,
Kolodny GM,
Braunwald E.
Pulmonary perfusion after rt-PA therapy for acute embolism: Early improvement assessed with segmental perfusion scanning. Radiology 1988; 166: 441-445
8
Higgins DL,
Bennett WF.
Tissue plasminogen activator: The biochemistry and pharmacology of variants produced by mutagenesis. Annu Rev Pharmacol Toxicol 1990; 30: 091-121
10
Madison EL.
Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis 1994; 8 (Suppl) (Suppl. 01) 221-236
12
Martin U,
von Mollendorf E,
Akpan W,
Kientsch-Engel R,
Kaufmann B,
Neugebauer G.
Thrombolysis with an E. coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemost 1991; 65: 550-564
13
Martin U,
Fischer S,
Kohnert U,
Lill H,
Rudolph R,
Sponer G,
Stem A,
Strein K.
Thrombolytic potency of an E. coli-produced novel variant of rt-PA in dogs. Fibrinolysis 1990; 4 (Suppl) (Suppl. 03) 9 (Abstract #26)
15
Smith GF,
Craft TJ,
Quay JF.
Pharmacodynamics of modified tissue plasminogen activator LY210825 in the conscious dog as evaluated with immunocapture assays. Fibrinolysis 1993; 7: 264-274
17
Jackson CV,
Crowe VG,
Trelia JC,
Sundboom JL,
Grinnell BW,
Bobbitt JL,
Burck PJ,
Quay JF,
Smith GF.
Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation 1990; 82: 930-940
19
Madison EL,
Goldsmith EJ,
Gething M-JH,
Sambrook JF,
Gerard RD.
Restoration of serine protease-inhibitor interaction by protein engineering. J Biol Chem 1990; 265: 21423-21426
21
Bennett WF,
Paoni NF,
Keyt BA,
Botstein D,
Jones AJS,
Presta L,
Wurm FM,
Zoller MJ.
High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991; 266: 5191-5201
24
Fay WP,
Eitzman DT,
Shapiro AD,
Madison EL,
Ginsburg D.
Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 -dependent and -independent mechanisms. Blood 1994; 83: 351-356
26
Madison EL,
Gething MJ,
Sambrook JF.
Mutations in at least five distinct regions increase the “fibrin selectivity” of tissue-type plasminogen activator. Fibrinolysis 1992; 6: 105 (Abstract #273)
29
Muschick P,
Zeggert D,
Donner P,
Witt W.
Thrombolytic properties of desmodus (vampire bat) salivary plasminogen activator DSPAα1, alteplase, and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis. Fibrinolysis 1993; 7: 284-290
31
Higgins DL,
Kelley RF,
Anderson S.
Laboratory-directed evolution: The road to an improved Activase®
. Proceedings of the BIOTECH USA 1989; 6: 463-466
32
Hinzmann B,
Wernicke D,
Pfeifer M,
Zacharias U,
Fischer B,
Eisenmenger F,
Will H.
Tissue-type plasminogen activator mutants imitating urokinase in the peptide link between kringle and protease domains and at selected sites within the protease domain. Eur J Biochem 1993; 213: 437-443
33
Kominger C,
Collen D.
Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: No evidence for a specific inhibitor. Thromb Haemost 1981; 46: 662-665
34
Holmes WE,
Lijnen HR,
Collen D.
Characterization of recombinant human-α2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. Biochemistry 1987; 26: 5133-5140
36
Gorman CM,
Gies DR,
McCray G.
Transient production of proteins using an adenovirus transformed cell line. DNA and Protein Engineering Techniques 1990; 2: 03-10
40
Hoylaerts M,
Rijken DC,
Lijnen HR,
Collen D.
Kinetics of the activation of plasminogen by tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919
41
Rijken DC,
Hoylaerts M,
Collen D.
Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-2925